Real-world safety of switching from originator to biosimilar natalizumab

被引：0
|
作者：
Brustad, Age Winje [1 ]
Hogestol, Einar [2 ,3 ,4 ]
Meling, Martine [2 ]
Celius, Elisabeth Gulowsen [2 ,4 ]
Berg-Hansen, Pal [2 ]
Konig, Marton [2 ,4 ]
Holterbakken, Trine Alm [2 ]
Warren, David [1 ]
Gehin, Johanna [1 ]
Bolstad, Nils [1 ]
Nygaard, Gro Owren [2 ,4 ]
机构：
[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
[2] Oslo Univ Hosp, Dept Neurol, Oslo, Norway
[3] Oslo Univ Hosp, Dept Psychol, Oslo, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1670/563
引用
收藏
页码：1056 / 1057
页数：2
相关论文
共 50 条
  • [41] SWITCHING TO BIOSIMILAR ADALIMUMAB: A REAL WORLD STUDY
    Begum, Julie
    Nisar, Muhammad K.
    RHEUMATOLOGY, 2020, 59
  • [42] Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
    Nabi, Hafsah
    Hendricks, Oliver
    Jensen, Dorte Vendelbo
    Loft, Anne Gitte
    Pedersen, Jens Kristian
    Just, Soren Andreas
    Danebod, Kamilla
    Munk, Heidi Lausten
    Kristensen, Salome
    Manilo, Natalia
    Colic, Ada
    Linauskas, Asta
    Thygesen, Pia Hoger
    Christensen, Louise Brot
    Kalisz, Maren Hogberget
    Lomborg, Niels
    Chrysidis, Stavros
    Raun, Johnny Lillelund
    Andersen, Marlene
    Mehnert, Frank
    Krogh, Niels Steen
    Hetland, Merete Lund
    Glintborg, Bente
    RMD OPEN, 2022, 8 (02):
  • [43] Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis
    Song, Seok Hyeon
    Woo, Se Joon
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024, 32 (08) : 1755 - 1759
  • [44] Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
    Cristina Vergara-Dangond
    Marina Sáez Belló
    Mónica Climente Martí
    Pilar Llopis Salvia
    Juan José Alegre-Sancho
    Drugs in R&D, 2017, 17 : 481 - 485
  • [45] Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
    Vergara-Dangond, Cristina
    Saez Bello, Marina
    Climente Marti, Monica
    Llopis Salvia, Pilar
    Jose Alegre-Sancho, Juan
    DRUGS IN R&D, 2017, 17 (03) : 481 - 485
  • [46] Natalizumab discontinuation in a Dutch real-world cohort
    Coerver, E. M. E.
    Wessels, M. H. J.
    van Lierop, Z. Y. G.
    van Kempen, Z. L. E.
    Killestein, J.
    Strijbis, E. M. M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [47] Natalizumab Treatment Outcomes and Safety Profile in Women with Multiple Sclerosis: Insights from Real-world Data
    Simsek, Yasemin
    Abasiyanik, Zuhal
    Samadzade, Ulvi
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 806 - 806
  • [48] Natalizumab discontinuation in a dutch real-world cohort
    Coerver, E.
    Wessels, M.
    Van Lierop, Z.
    Van Kempen, Z.
    Killestein, J.
    Strijbis, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 347 - 348
  • [49] COMPARISON OF EFFICACY AND SAFETY OF BIOSIMILAR RITUXIMAB AND ORIGINATOR RITUXIMAB IN REAL CLINICAL PRACTICE
    Kusevich, D.
    Olyunin, Y.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1131 - 1131
  • [50] A SURVEY OF RHEUMATOLOGY PATIENTS' SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS
    Ng, C. R.
    Samec, S.
    Kavanagh, P.
    Mccarthy, G.
    Donnelly, S.
    Wilson, A. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1427 - 1427
12345